Previous close | 6.06 |
Open | 8.12 |
Bid | 7.25 |
Ask | 7.70 |
Strike | 71.00 |
Expiry date | 2024-05-31 |
Day's range | 8.12 - 8.12 |
Contract range | N/A |
Volume | |
Open interest | 8 |
On Thursday, Tango Therapeutics Inc. (NASDAQ:TNGX) announced that it will discontinue the development of its TNG348 program. “Patient safety is always our first priority and based on emerging data from the TNG348 dose escalation study, we have made the decision to discontinue further development of this molecule due to liver toxicity experienced by patients in the trial. While disappointing, we believe this is the right decision given the data at hand,” said Barbara Weber, President and CEO. “We
WILMINGTON, Del., May 23, 2024--AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of investigational amyloidosis therapies at the International Symposium on Amyloidosis (ISA), in Rochester, MN from May 26–30, 2024.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.